Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

29.95
+2.017.19%
Volume:2.56M
Turnover:75.43M
Market Cap:3.36B
PE:-29.70
High:30.55
Open:27.78
Low:27.71
Close:27.94
Loading ...

Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan

Viking Therapeutics’ VK2735: A Promising Contender in the Weight-Loss Market with Superior Efficacy Profile

TIPRANKS
·
17 Jan

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

Motley Fool
·
17 Jan

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

Zacks
·
16 Jan

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Motley Fool
·
15 Jan

Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know

Zacks
·
14 Jan

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

LLY Falls Around 14% in 3 Months: How to Play the Stock

Zacks
·
09 Jan

Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

Zacks
·
09 Jan

Positive Buy Rating on Viking Therapeutics Driven by Promising VK2735 Program Advances

TIPRANKS
·
09 Jan

Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating

TIPRANKS
·
09 Jan

Viking Therapeutics’ oral-2735 could differentiate asset, says JPMorgan

TIPRANKS
·
09 Jan

Viking Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 Jan

Viking Therapeutics’ Promising Phase 2 Trial and Competitive Edge Justify Buy Rating

TIPRANKS
·
08 Jan

Viking Therapeutics Announces Initiation of Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity

THOMSON REUTERS
·
08 Jan

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

PR Newswire
·
08 Jan